Below are resources created to help you learn about Somatuline® Depot (lanreotide) Injection 120 mg for the treatment of your patients with gastrointestinal and pancreatic neuroendocrine tumors (NETs).
*Based on actual patient cases; names and images are representative only.
Dr. Alexandria Phan, Director of GI Medical Oncology at the Houston Methodist Hospital, reviews the important clinical benefits of Somatuline Depot. She highlights the efficacy results of the landmark clinical trial, CLARINET (Controlled Study of Lanreotide Antiproliferative Response In NeuroEndocrine Tumors), and discusses the dosing and administration process. Click the image to watch the video.
The unique formulation of Somatuline Depot—from its liquid crystal technology to its sustained-release activity—permits once-monthly dosing. Click the image to watch the video.
Somatuline® Depot (lanreotide) Injection 120 mg is indicated for the treatment of adult patients with unresectable, well- or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.
Somatuline Depot is contraindicated in patients with hypersensitivity to lanreotide. Allergic reactions (including angioedema and anaphylaxis) have been reported following administration of lanreotide.
In the GEP-NET pivotal trial, the most common adverse reactions (incidence of >10% and more common than placebo) in patients treated with Somatuline Depot vs placebo were abdominal pain (34% vs 24%), musculoskeletal pain (19% vs 13%), vomiting (19% vs 9%), headache (16% vs 11%), injection site reaction (15% vs 7%), hyperglycemia (14% vs 5%), hypertension (14% vs 5%), and cholelithiasis (14% vs 7%).
Reference 1. Data on file. Basking Ridge, NJ: Ipsen Biopharmaceuticals, Inc; 2007.